FundamentalVR Announces Expansion into Endovascular Surgery

FundamentalVR, global pioneers in immersive VR surgical skills training and performance data, today announced the addition of endovascular surgery to its expanding suite of haptic surgical training procedures.

Alongside this capability for new endovascular procedures, the company also offers CollaborationVR, a personalized virtual space with unlimited capacity specifically designed for healthcare professionals to meet and accelerate procedural and product adoption together.

A leading player in surgical education, FundamentalVR’s simulations are delivered through its Fundamental Surgery platform. The platform is powered by the company’s unique HapticVRTM technology which mimics the physical cues of surgical actions, tools, and tissue textures felt in real-life surgery. FundamentalVR provides a gold standard of immersive surgical training using these technologies, and their immersive learning platform has already delivered success for medical device and pharmaceutical companies across orthopedics, general surgery, robotics, and ophthalmology.

In creating high-fidelity simulations for a variety of specialisms, the platform is enabling medical institutions and life science organizations to remotely train personnel en masse without having to compromise on quality. By leveraging CollaborationVR, HapticVR and other features on the Fundamental Surgery platform, FundamentalVR ensures that personnel are given the dynamic environment needed to explore patient cases, anatomy, devices, procedures and more to achieve their learning goals. Including implementing virtual products, which customers can build as direct replicas of real-life devices.

With such credentials, the Fundamental Surgery platform is well equipped to simulate Image-Guided Interventional procedures all with full haptic feedback and high-resolution graphics. Examples include Acute Ischemic Stroke, EVAR, Cardiac Rhythm Management, Coronary Interventions, and Carotid Interventions.

“Our solutions can be adapted to multiple procedures and tools and remain the only medical VR education platform accredited by the Royal College of Surgeons” says Richard Vincent, co-founder and CEO of FundamentalVR.

By creating low-cost, “pre-human” immersive simulations, FundamentalVR dramatically accelerates the transfer of skills and the adoption of new procedures, tools, and equipment at scale and more economically than ever before.

Already deployed across the globe for use by medical device makers and centers of excellence, Fundamental Surgery’s equipment-agnostic nature allows it to work with a range of off-the-shelf hardware. Its notable benefits to medical educators and life science companies include:

  • Blended Immersive Technology: Offers various modalities that fit each stage of the learning pathway to provide unparalleled flexibility. Depending on each business use case, they can be used individually or together, ultimately reducing time and cost while increasing capability and confidence.
  • Enhanced market penetration: Enables life science companies to experiment and conduct trials more conveniently anywhere, anytime, with surgeons on new techniques, therapies, and products, reducing barriers to bringing new tools to market.
  • Multiuser platform using CollaborationVR: Allows for an unlimited number of users to meet, interact, and teach within virtual classrooms and operating rooms. Join, monitor, and access remotely from anywhere in the world.
  • Scalability: The low-cost platform is compatible with off-the-shelf hardware and can be transported easily. It enables a scalable software-based platform that is future-proof, creating a robust infrastructure to ensure the investment does not date as hardware improves.
  • Data and Cloud-Based Analytics: Every user interaction and decision is measured and recorded in detail, with metrics including economy of movement, 3D spatial awareness, surgical gaze, respect for tissue, and human factors such as dealing with adverse events and complications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”